Kevin Forrest *05 MOL
Biotech, Executive
CEO, ReyjaBio
Kevin Forrest is co-founder and CEO of ReyjaBio, a recently formed venture-backed company focused on identifying and advancing technologies primarily from top academic universities and research institutes. Prior to ReyjaBio, Forrest was founding CEO of Kate Therapeutics, a muscle-directed gene therapy company that he led from inception through sale to Novartis in late 2024. Prior to Kate, Forrest was founding CEO of Expansion Therapeutics, a small molecule RNA targeting company, and COO/CFO of Cidara Therapeutics (Nasdaq: CDTX) an infectious-disease company he founded and took public. Prior to Cidara, he was a principal at 5AM Ventures, a life science venture capital firm. Forrest obtained a B.S. in biology from Boston College and Ph.D. in molecular biology from Princeton University, where he developed novel imaging systems to study RNA localization and translational control.